Welgo

Welgo (Hangzhou Welgo Medical Technology) is a clinical-stage biotechnology company based in China that focuses on the development of innovative therapies for metabolic diseases. The company specializes in multi-receptor agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors, to treat obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, WLG-03, is a triple agonist designed to provide superior weight loss and metabolic benefits compared to existing single or dual-target therapies. Welgo utilizes a proprietary peptide engineering platform to optimize the potency and pharmacokinetic profiles of its drug candidates. The company is backed by prominent venture capital firms and aims to address significant unmet needs in the global metabolic health market.